IMPACT OF SWITCHING PROPHYLAXIS TREATMENT FROM FACTOR VIII TO EMICIZUMAB IN HEMOPHILIA A PATIENTS WITHOUT INHIBITORS

被引：0
|
作者：
Escobar, Miguel [1 ]
Agrawal, Neha [2 ]
Chatterjee, Sagnik [2 ]
Bhattacharya, Swastik [2 ]
Caicedo, Jorge [3 ]
Bullano, Michael [3 ]
Schultz, Robert G. [3 ]
机构：
[1] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA
[2] Complete HEOR Solut, New Wales, PA USA
[3] Takeda Pharmaceut USA Inc, Lexington, MA USA
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2023年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E34 / E34
页数：1
相关论文
共 50 条
  • [1] Impact of switching prophylaxis treatment from factor VIII to emicizumab in hemophilia A patients without inhibitors
    Escobar, Miguel
    Agrawal, Neha
    Chatterjee, Sagnik
    Bhattacharya, Swastik
    Caicedo, Jorge
    Bullano, Michael
    Schultz, Bob G. G.
    JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 574 - 580
  • [2] A real-world evidence analysis of the impact of switching from factor VIII to emicizumab prophylaxis in patients with hemophilia A without inhibitors
    Escobar, Miguel
    Bullano, Michael
    Mokdad, Ali G.
    Caicedo, Jorge
    Schultz, Bob G.
    Fan, Qi
    Verma, Sumit
    EXPERT REVIEW OF HEMATOLOGY, 2023, 16 (06) : 467 - 474
  • [3] Emicizumab prophylaxis overcomes factor VIII inhibitors in Hemophilia A
    Shima, Midori
    JOURNAL OF PEDIATRICS, 2017, 190 : 289 - 289
  • [4] ECONOMIC IMPACT OF EMICIZUMAB PROPHYLAXIS FOR HEMOPHILIA A WITH AND WITHOUT INHIBITORS
    Cortesi, P. A.
    Castaman, G.
    Mantovani, L. G.
    VALUE IN HEALTH, 2020, 23 : S699 - S699
  • [5] Emicizumab for hemophilia A with factor VIII inhibitors
    Young, Guy
    Callaghan, Michael
    Dunn, Amy
    Kruse-Jarres, Rebecca
    Pipe, Steven
    EXPERT REVIEW OF HEMATOLOGY, 2018, 11 (11) : 835 - 846
  • [6] Emicizumab Prophylaxis in Patients with Hemophilia. with and without Inhibitors
    Ebbert, Patrick T.
    Xavier, Frederico
    Seaman, Craig D.
    Ragni, Margaret V.
    BLOOD, 2019, 134
  • [7] EMICIZUMAB PROPHYLAXIS FOR THE TREATMENT OF INFANTS WITH SEVERE HEMOPHILIA A WITHOUT FACTOR VIII INHIBITORS: PRIMARY ANALYSIS OF THE HAVEN 7 STUDY
    Pipe, Steven W.
    Collins, Peter
    Dhalluin, Christophe
    Kenet, Gili
    Schmitt, Christophe
    Buri, Muriel
    Jimenez-Yuste, Victor
    Peyvandi, Flora
    Young, Guy
    Oldenburg, Johannes
    Mancuso, Maria Elisa
    Kavakli, Kaan
    Kiialainen, Anna
    Niggli, Markus
    Chang, Tiffany
    Lehle, Michaela
    Fijnvandraat, Karin
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 100 : 99 - 99
  • [8] Emicizumab use in females with moderate or mild hemophilia A without factor VIII inhibitors who warrant prophylaxis
    Hermans, Cedric
    Ventriglia, Giuliana
    Obaji, Samya
    Beckermann, Benjamin M.
    Lehle, Michaela
    Catalani, Olivier
    d'Oiron, Roseline
    Frenzel, Laurent
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2023, 7 (08)
  • [9] Emicizumab Prophylaxis for the Treatment of Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Interim Analysis of the HAVEN 7 Study
    Pipe, Steven W.
    Collins, Peter
    Dhalluin, Christophe
    Kenet, Gili
    Schmitt, Christophe
    Buri, Muriel
    Jimenez-Yuste, Victor
    Peyvandi, Flora
    Young, Guy
    Oldenburg, Johannes
    Mancuso, Maria Elisa
    Kiialainen, Anna
    Chang, Tiffany
    Lehle, Michaela
    Fijnvandraat, Karin
    BLOOD, 2022, 140
  • [10] Surgical Experience from the STASEY Study of Emicizumab Prophylaxis in People with Hemophilia A with Factor VIII Inhibitors
    Castaman, Giancarlo
    Peyvandi, Flora
    Hovinga, Johanna A. Kremer
    Schutgens, Roger E. G.
    Robson, Susan
    Moreno, Katya
    Jimenez-Yuste, Victor
    TH OPEN, 2024, 08 (01) : e42 - e54
12345